Related Experiment Video
Updated: Mar 17, 2026

13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.4K
KLSD: A Curated Kinase-Ligand Database Mapping Selectivity Landscapes and Polypharmacology.
Cheng Chen1, Yuqian Yuan2, Hongyan Li1,3
1School of Artificial Intelligence and Information Technology, Nanjing University of Chinese Medicine, Nanjing 210023, China.
ACS Omega
|March 16, 2026
Summary
We developed KLSD, a database of small-molecule kinase inhibitors and their activities, alongside a dual-task model predicting potency and selectivity for drug discovery.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Pharmacology
Background:
- Kinase inhibitors are crucial in drug discovery, but understanding their selectivity and polypharmacology is complex.
- Existing resources often lack comprehensive quantitative activity data and selectivity profiles.
- Developing predictive models for kinase inhibitor activity and selectivity is essential.
Purpose of the Study:
- To create KLSD, a large-scale curated database of small-molecule kinase inhibitors and their quantitative activity records.
- To develop a dual-task ensemble model for simultaneously predicting kinase inhibitor potency (pAct) and selectivity.
- To provide a valuable resource for advancing kinase inhibitor research and drug discovery.
Main Methods:
- Curated a database (KLSD) of 787,213 small-molecule kinase inhibitors with 1.8 million quantitative activity records across 428 human kinases.
- Developed a dual-task ensemble model using a multibranch residual multilayer perceptron (MLP) augmented with various machine learning and graph network approaches (SVM, RF, XGBoost, CNN, GCN, GAT, RGCN, VAE).
- Utilized continuous potency labels instead of categorical classes for improved predictive resolution.
Main Results:
- The KLSD database provides extensive data on kinase inhibitor selectivity and polypharmacology.
- The dual-task ensemble model achieved high classification accuracies (≥0.84 per kinase, 0.98 overall) when benchmarked on the JAK family (JAK1/2/3, TYK2).
- The model demonstrated strong generalizability across different kinases.
Conclusions:
- KLSD is a comprehensive resource for kinase inhibitor research, facilitating studies on selectivity and polypharmacology.
- The developed ensemble model accurately predicts kinase inhibitor potency and selectivity, offering a powerful tool for drug discovery.
- Both the KLSD database and the predictive models are freely available to the research community.
More Related Videos
Related Concept Videos
Ligand Binding and Linkage
5.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.9K
Ligand Binding Sites
15.7K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
15.7K
Ligand Binding Sites
9.0K
9.0K
Structure-Activity Relationships and Drug Design
2.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
2.0K
Drug Discovery: Overview
12.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.8K
Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73

